

## FEDERAL LAWS AND REGULATIONS REFERENCES

1. SAMSHA. [National Survey of Substance Abuse Treatment Services \(N-SSATS\): 2014.](#) ; 2016.
2. Alford DP, Labelle CT, Kretsch N, et al. [Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.](#) *Arch Intern Med.* 2011;171(5):425-431.
3. Pade PA, Cardon KE, Hoffman RM, et al. [Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.](#) *J Subst Abuse Treat.* 2012;43(4):446-450.
4. Kahan M, Srivastava A, Ordean A, et al. [Buprenorphine: new treatment of opioid addiction in primary care.](#) *Can Fam Physician.* 2011;57(3):281-289.
5. FSMB. [Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office.](#) *FSMB Website.* 2013.
6. SAMHSA/CSAT. [Confidentiality of Patient Records for Alcohol and Other Drug Treatment.](#) Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
7. SAMHSA. [Substance Abuse Confidentiality Regulations.](#) 2015.
8. SAMHSA/CSAT. [Intensive Outpatient Treatment for Alcohol and Other Drug Abuse.](#) Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 1994.
9. Stanton A, McLoed C, Luckey B, et al. [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program.](#) 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
10. SAMHSA. [Physician and Program Data.](#) *SAMHSA.gov.* 2018.
11. U.S. Census Bureau. [2012 Statistical Abstract of the United States.](#) *Census.gov.* 2012.